Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2001-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/j.1365-2036.2001.01087.xPMID 11563995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole

  2001cited by this paper
• The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH

  2000cited by this paper
• Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects

  2000cited by this paper
• Presentation of the Julius M. Friedenwald medal to Howard M. Spiro, M.D.

  2000cited by this paper
• Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)

  2000cited by this paper
• Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

  2000cited by this paper
• Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

  1997cited by this paper
• Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

  1996cited by this paper
• Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study

  1996cited by this paper
• Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.

  1992cited by this paper
• The Pharmacokinetics of Single and Repeated Once-Daily Doses of 10, 20 and 40mg Omeprazole as Enteric-Coated Granules

  1991cited by this paper
• The mechanism of action of the gastric acid secretion inhibitor omeprazole.

  1986cited by this paper
• Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

  1984cited by this paper
• Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

  1983cited by this paper

• Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency.

  2026cites this paper
• Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality

  2025cites this paper
• A Critical Appraisal of Enantiomer Concept of Proton Pump Inhibitors.

  2025cites this paper
• Determination of Potential Genotoxic Impurities in Esomeprazole Magnesium by HPLC–MS/MS

  2025cites this paper
• Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study

  2025cites this paper
• Effect of Omeprazole on Esophageal Microbiota in Dogs Detected Using a Minimally Invasive Sampling Method

  2025cites this paper
• Pharmaceutical treatment of equine glandular gastric disease: A contextualised review of recent developments

  2024cites this paper
• Gastroprotective effect of rhodanine and 2,4-thiazolidinediones scaffolds in rat stomachs by contribution of anti-apoptotic (BCL-2) and tumor suppressor (P53) proteins

  2024cites this paper
• The Effects of Omeprazole on the Neuron-like Spiking of the Electrical Potential of Proteinoid Microspheres

  2024cites this paper
• Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats.

  2024cites this paper
• Comparison of oral esomeprazole and oral omeprazole in the treatment of equine squamous gastric disease.

  2023cites this paper
• Preclinical Evaluation of Esomeprazole Safety and Toxicokinetics

  2023cites this paper
• Review Artikel: Sintesis dan Isomerisasi Senyawa Kimia pada Obat

  2023cites this paper
• Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric‐Coated Capsules in Healthy Chinese Subjects

  2023cites this paper
• Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole

  2022cites this paper
• Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction

  2022cites this paper
• Esomeprazole and apixaban pharmacokinetic interactions in healthy rats

  2022cites this paper
• Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia

  2022influential citation
• Application in Drugs and Materials

  2021cites this paper
• Synchronized determination of sacubitril and valsartan with some co-administered drugs in human plasma via UPLC-MS/MS method using solid phase extraction.

  2021cites this paper
• Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry

  2021cites this paper
• Esomeprazole in the treatment of equine glandular gastric disease

  2021cites this paper
• The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy

  2020cites this paper
• Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir

  2020cites this paper
• Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

  2020cites this paper
• Proton-Pump Inhibitors in Adults and Pediatric Patients: Use and Abuse

  2020cites this paper
• Analysis of the symptom response to esomeprazole 20 mg over days 1–4 of a 14-day course of treatment for frequent heartburn: results of two randomised controlled trials

  2019influential citation
• Pharmacokinetic study of anti-tb drug para-aminosalicylic acid and its metabolites: a possible relationship with the development of toxicity

  2019cites this paper
• Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study

  2019cites this paper
• Synthesis and characterization of one impurity in esomeprazole, an antiulcerative drug

  2019cites this paper
• Probing the Role of Imidazopyridine and Imidazophosphorine Scaffolds To Design Novel Proton Pump Inhibitor for H+,K+-ATPase: A DFT Study

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs

  2018cites this paper
• Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

  2018cites this paper
• A Comparative Study of Sepiae Os, Arcae Concha, Ostreae Concha and Esomeprazole in a Mouse Model of Reflux Esophagitis

  2018cites this paper
• ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

  2018cites this paper
• Interconnection of sulfides and sulfoxides in medicinal chemistry

  2018cites this paper
• Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment

  2018cites this paper
• Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection

  2018cites this paper
• Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial

  2018cites this paper
• Stereoselective Metabolism of Omeprazole by Cytochrome P450 2C19 and 3A4: Mechanistic Insights from DFT Study.

  2018cites this paper
• Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options

  2017cites this paper
• First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease

  2017cites this paper
• Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors.

  2016cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers

  2016cites this paper
• Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.

  2016cites this paper
• Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs

  2016cites this paper
• Non-prescription proton-pump inhibitors for self-treating frequent heartburn:the role of the Canadian pharmacist

  2016cites this paper
• Rhabdomyolysis associated with single-dose intravenous esomeprazole administration

  2016cites this paper
• Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes

  2016cites this paper
• Designing Irreversible Inhibitors—Worth the Effort?

  2016cites this paper
• The Indications, Applications, and Risks of Proton Pump Inhibitors.

  2016cites this paper
• Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

  2016cites this paper
• Implications of Pharmacogenetics for Antimicrobial Prescribing

  2016cites this paper
• The effect of the proton pump inhibitor pantoprazole on the biology of Campylobacter jejuni

  2016cites this paper
• Dose-dependent esomeprasole antisecretory effect: results of long-term intragastric pH monitoring

  2016cites this paper
• Dexlansoprazole – a new-generation proton pump inhibitor

  2015cites this paper
• Fasting Urinary Calcium‐to‐Creatinine and Oxalate‐to‐Creatinine Ratios in Dogs with Calcium Oxalate Urolithiasis and Breed‐Matched Controls

  2015cites this paper
• The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors

  2015cites this paper
• Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers.

  2015cites this paper
• Central pontine myelinolysis: analysis of six cases

  2015cites this paper
• Wpływ farmakologicznej modyfikacji reakcji zapalnej na wyniki leczenie zapalenia żołądka wywołanego zakażeniem Helicobacter pylor

  2014cites this paper
• Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium)

  2014cites this paper
• Evaluation of the Effect of Orally Administered Acid Suppressants On Intragastric pH in Cats

  2014cites this paper
• CYP2C19 polymorphisms in drug metabolism and response

  2014cites this paper
• Evidence‐based treatment of frequent heartburn: The benefits and limitations of over‐the‐counter medications

  2014cites this paper
• The Stereoselectivity of CYP2C19 on R‐ and S‐isomers of Proton Pump Inhibitors

  2014cites this paper
• Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3.

  2014cites this paper
• V-ATPase as an effective therapeutic target for sarcomas.

  2014cites this paper
• Pharmacogenomics of antimicrobial agents.

  2014cites this paper
• Omeprazole and Lansoprazole Enantiomers Induce CYP3A4 in Human Hepatocytes and Cell Lines via Glucocorticoid Receptor and Pregnane X Receptor Axis

  2014cites this paper
• Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease

  2014influential citation
• Differential Effects of Omeprazole and Lansoprazole Enantiomers on Aryl Hydrocarbon Receptor in Human Hepatocytes and Cell Lines

  2014cites this paper
• Wpyw farmakologicznej modyfikacji reakcji zapalnej na wyniki leczenia zapalenia żo¯ądka wywoanego zaka żeniem Helicobacter pylori

  2014cites this paper
• The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

  2013influential citation
• The Inhibition of Monoamine Oxidase by Esomeprazole

  2013cites this paper
• V-ATPase as an effective therapeutic target for sarcomas.

  2013cites this paper
• Letter: lansoprazole consumption is more common in Japanese patients with collagenous colitis – authors’ reply

  2013cites this paper
• Benzimidazole‐Based H+/K+‐ATPase Inhibitors for the Treatment of Gastroesophageal Reflux Disease

  2013cites this paper
• Discovery and Development of Proton Pump Inhibitors

  2013cites this paper
• Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

  2013cites this paper
• Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole

  2013cites this paper
• CYP2C19 genotypes determine the efficacy of on‐demand therapy of pantoprazole for reflux esophagitis as Los‐Angeles grades C and D

  2012cites this paper
• Efficacy of S-Pantoprazole 20 mg Compared with Pantoprazole 40 mg in the Treatment of Reflux Esophagitis: A Randomized, Double-Blind Comparative Trial

  2012influential citation
• Clinical Pharmacology of Proton Pump Inhibitors

  2012cites this paper
• Old Drugs Yield New Discoveries: Examples from the Prodrug, Chiral Switch, and Site‐Selective Deuteration Strategies

  2012cites this paper
• INIBIDORES DA BOMBA DE PRÓTONS: REVISÃO E ANÁLISE FARMACOECONÔMICA

  2012cites this paper
• Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients

  2012cites this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2012cites this paper
• A Pharmacological Approach to Gastric Acid Inhibition

  2012cites this paper
• Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes

  2012cites this paper
• Agranulocytosis induced by proton pump inhibitors.

  2012influential citation
• A rationale for the use of proton pump inhibitors as antineoplastic agents.

  2012cites this paper
• Efficacy of esomeprazole in treating acid-related diseases in Japanese populations

  2012cites this paper
• Omeprazole Impairs the Absorption of Mycophenolate Mofetil But Not of Enteric‐Coated Mycophenolate Sodium in Healthy Volunteers

  2012cites this paper
• Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two‐way crossover study including CYP2C19 genotyping

  2011cites this paper
• Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment

  2011cites this paper
• Pharmacogenetic Aspects and Drug Interactions in Anticoagulation Therapy with Coumarins

  2011cites this paper
• Update on the pharmacogenomics of proton pump inhibitors.

  2011cites this paper
• Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis

  2011cites this paper
• A Randomized, Controlled, Crossover Trial to Investigate Times to Onset of the Perception of Soothing and Cooling by Over-The-Counter Heartburn Treatments

  2010cites this paper